Drug intelligence / Profile preview

ION356

Development stage
Phase 1
Lead developer
Ionis Pharmaceuticals
Modality
Gene Therapies, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intrathecal
01

Overview

ION356 is an investigational antisense oligonucleotide (ASO) developed by Ionis Pharmaceuticals for the treatment of Pelizaeus-Merzbacher disease (PMD), a rare, severe leukodystrophy caused by duplications or mutations in the PLP1 gene. The drug is designed to silence or inhibit expression of the PLP1 gene, thereby reducing levels of proteolipid protein 1 and addressing the underlying cause of PMD. It is administered via intrathecal injection and has received Orphan Drug Designation and Rare Pediatric Disease Designation from regulatory authorities. Clinical trials are ongoing to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric patients with classic PMD[2][4][5][6][7][9][10].

Other names
ION-356ION356ION 356

Beyond the preview

Go deeper on ION356.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ION356.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call